Neuroimaging Core

项目总结-神经影像核心（NIC） IADRC的NIC将作为老龄化和神经变性的区域和国家资源 研究社区提供访问，并合作支持，应用先进的 临床和转化研究中的神经影像学。国家信息中心在发展和 在神经成像和成像遗传学分析中实施尖端的协议和技术， 与NIA资助的倡议合作（例如，ADNI、DIAN、ADGC等），并提供培训， 神经影像学和成像遗传学的各个层次和学科的科学家。在此应用中，NIC将 追求以下具体目标：（1）支持IADRC，IU老龄化研究中心， 以及目前采用或可能受益于先进神经成像的相关项目;（2）提供 标准化的，最先进的神经影像采集和分析协议;（3）扩展跨学科 区域神经科学研究，使用先进的神经成像工具研究疾病机制， （4）支持和合作主要的国家和国际AD相关的 使用神经影像学和遗传学方法的研究联盟;（5）提供跨学科的教育 AD和其他退行性疾病的神经影像学和遗传学的机会， 从本科生到博士后研究员和教职员工的各级科学家，以及传播 神经影像学的结果。NIC与临床核心密切合作，将执行 最先进的多模式MRI（Siemens Prisma 3 T：高分辨率结构、3D pCASL灌注、多频带静息- 基于状态和任务的fMRI，以及针对结构和功能连接体优化的混合扩散和DTI 分析），以及>200名IADRC参与者的淀粉样蛋白和/或tau PET。 临床前或早期症状阶段的参与者（例如，主观认知下降或轻度认知 损伤），迟发性AD，以及来自痴呆症致病突变家族的个体， 优先。影像学与病理学的相关性将有助于提高对早期结构， 在体内观察到的功能和分子变化，可能有助于确定新的治疗靶点。交叉- 模态图像分析和ADNI、DIAN和其他成像遗传学研究的结果将有助于 在早期检测、机制理解和优化成像方面取得进展，作为动态生物标志物， 研究治疗效果。获取标准化的最先进的MRI和PET数据，供许多 研究人员将提高研究效率，并促进定量分析。与其他核心集成 将允许IADRC通过将成像生物标志物与神经心理学联系起来， 测量、神经病理学样本、遗传和其他组学标记。国家信息中心将继续促进和 通过地方、区域和国家/国际合作支持先进的成像研究。网卡 将推进AD成像研究，以实现NAPA到2025年预防和有效治疗AD的目标。

Project Summary – Neuroimaging Core (NIC) The NIC of the IADRC will serve as a regional and national resource for the aging and neurodegeneration research community by providing access to, and collaborative support for, the application of advanced neuroimaging in clinical and translational research. The NIC has been productive in developing and implementing cutting-edge protocols and techniques in neuroimaging and imaging genetics analysis, collaborating with NIA-funded initiatives (e.g., ADNI, DIAN, ADGC, etc.), and in providing training in neuroimaging and imaging genetics to scientists of all levels and disciplines. In this application, the NIC will pursue the following specific aims: (1) Support funded research in the IADRC, IU Center for Aging Research, and related programs that currently employ or could benefit from advanced neuroimaging; (2) Provide standardized, state-of-the-art neuroimaging acquisition and analysis protocols; (3) Expand transdisciplinary regional neuroscience research using advanced neuroimaging tools to study disease mechanisms and treatments for neurodegeneration; (4) Support and collaborate with major national and international AD-related research consortia using neuroimaging and genetics methods; (5) Provide transdisciplinary educational opportunities in neuroimaging and genetics of AD and other degenerative disorders for basic and clinical scientists at all levels from undergraduates to post-doctoral fellows and faculty, as well as dissemination of neuroimaging results to the community. The NIC, working closely with the Clinical Core, will perform state-of- the-art multimodal MRI (Siemens Prisma 3T: high resolution structural, 3D pCASL perfusion, multiband resting- state and task-based fMRI, and hybrid diffusion and DTI optimized for structural and functional connectome analysis) on all eligible IADRC participants, as well as amyloid and/or tau PET on >200 IADRC participants. Participants in preclinical or early symptomatic phases (e.g., subjective cognitive decline or mild cognitive impairment), late-onset AD, and individuals from families with mutations causal for dementias will be prioritized. Imaging-pathologic correlation when available will improve the understanding of early structural, functional, and molecular changes observed in vivo and may help identify novel therapeutic targets. Cross- modality image analyses and results of imaging genetics studies with ADNI, DIAN, and others will contribute to advances in early detection, mechanistic understanding, and optimize imaging as a dynamic biomarker to study therapeutic effects. Acquiring standardized state-of-the-art MRI and PET data for use by many investigators will increase research productivity and facilitate quantitative analyses. Integration with other cores will allow the IADRC to expand on these analyses by relating imaging biomarkers to neuropsychological measures, neuropathologic samples, genetic and other –omics markers. The NIC will continue to foster and support advanced imaging research through local, regional, and national/international collaborations. The NIC will advance AD imaging research to meet the goal of NAPA for preventing and effectively treating AD by 2025.